• Earlier in January 2026, Bruker’s Energy & Supercon Technologies (BEST) division announced two expanded multi-year superconductor supply agreements for MRI magnets, with a combined expected value of about US$500 million and durations including one contract extending up to seven years.
• By deepening long-term relationships with global radiology manufacturers and supporting helium-free MRI architectures, BEST is reinforcing Bruker’s role in enabling next-generation medical imaging and wider superconductivity applications.
• Next, we’ll examine how these expanded multi-year MRI superconductor contracts may influence Bruker’s existing investment narrative and future expectations.

We've found 12 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Bruker Investment Narrative Recap

To own Bruker, you need to believe that demand for its advanced scientific and medical technologies will recover and that management can convert this into sustainable profitability. The new US$500 million BEST MRI superconductor agreements add long-duration, contract-based revenue, but do not fundamentally change the near term dependence on a rebound in research and biopharma spending or the risk that ongoing weak orders could pressure earnings.

The most relevant recent announcement here is Bruker’s participation in the 44th Annual J.P. Morgan Healthcare Conference in January 2026, where management has an opportunity to frame how these multi year MRI superconductor contracts fit into its margin improvement and earnings recovery plans. For investors, aligning that message with existing guidance and cost reduction goals will be important.

However, investors should also be aware that if book to bill weakness persists and backlog erodes, then...

Bruker's narrative projects $3.8 billion revenue and $404.1 million earnings by 2028.

Uncover how Bruker's forecasts yield a $52.36 fair value, a 6% upside to its current price.

Exploring Other Perspectives

Five members of the Simply Wall St Community place Bruker’s fair value between US$31.30 and US$75.00, underscoring how far opinions can spread. You should weigh those views against the risk that prolonged funding pressures and soft order intake could continue to hold back Bruker’s revenue and earnings recovery, and explore several contrasting scenarios before forming a view.

Explore 5 other fair value estimates on Bruker - why the stock might be worth as much as 52% more than the current price!

Build Your Own Bruker Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Bruker research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Bruker research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bruker's overall financial health at a glance.

Seeking Other Investments?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Find companies with promising cash flow potential yet trading below their fair value.
• Outshine the giants: these 24 early-stage AI stocks could fund your retirement.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.